Journal of Ophthalmology / 2016 / Article / Tab 1

Clinical Study

Comparison of Two Botulinum Neurotoxin A Injection Patterns with or without the Medial Lower Eyelid in the Treatment of Blepharospasm

Table 1

Between-group comparisons of ocular surface parameters and subjective symptoms in the MLE Group and the non-MLE Group before and after BoNT-A injection.

Baseline (M (SD))0One week (M (SD)) (M (SD))One month (M (SD)) (M (SD))Three months (M (SD)) (M (SD))

Tear BUT, sMLE 4.26 (2.83)6.32 (3.57)2.06 (4.33)5.68 (3.00)1.41 (3.61)5.47 (3.20)1.21 (2.65)
Non-MLE 4.15 (2.71)6.09 (4.20)1.94 (4.76)5.29 (2.69)1.15 (3.53)5.09 (2.21)0.94 (2.35)
Difference (95% CI)0.12 (−0.31 to 0.55)0.12 (−0.76 to 1.03)0.26 (−0.33 to 0.86)0.26 (−0.68 to 1.21)
value0.6080.7470.4090.807

Schirmer I test, mmMLE 8.59 (5.09)13.82 (6.45)5.24 (4.92)12.09 (5.94)3.50 (4.32)9.53 (4.35)0.94 (3.27)
Non-MLE 8.91 (4.68)11.21 (6.00)2.29 (4.19)10.76 (5.27)1.85 (4.09)9.32 (4.05)0.41 (2.63)
Difference (95% CI)−0.32 (−1.46 to 0.81)2.94 (1.41 to 4.47)1.65 (0.20 to 3.10)0.53 (−0.65 to 1.71)
value0.5660.0000.0270.369

Lower lid TMH, mmMLE 0.22 (0.13)0.38 (0.17)0.16 (0.17)0.30 (0.14)0.08 (0.12)0.23 (0.13)0.01 (0.07)
Non-MLE 0.21 (0.09)0.32 (0.14)0.11 (0.13)0.27 (0.12)0.06 (0.11)0.22 (0.09)0.01 (0.06)
Difference (95% CI)0.01 (−0.02 to 0.04)0.05 (0.01 to 0.10)0.01 (−0.02 to 0.04)0.00 (−0.02 to 0.02)
value 0.6600.0120.3360.535

Lagophthalmos height, mmMLE 01.16 (0.95)1.16 (0.95)0.11 (0.38)0.11 (0.38)00
Non-MLE 00.73 (0.81)0.73 (0.81)0.12 (0.39)0.12 (0.39)00
Difference (95% CI)0.44 (0.20 to 0.67)−0.01 (−0.06 to 0.04)
value0.0010.655

JRS score, pointsMLE 7.70 (0.92)1.82 (1.55)−5.89 (1.65)0.24 (0.83)−7.45 (1.18)0.88 (1.52)−6.82 (1.65)
Non-MLE 7.70 (0.92)1.94 (1.48)−5.76 (1.56)0.30 (0.88)−7.39 (1.20)1.88 (1.60)−5.82 (1.78)
Difference (95% CI)−0.12 (−0.29 to 0.05)−0.06 (−0.18 to 0.06)−1.00 (−1.35 to −0.65)
value0.1570.3170.000

.